6,403 reports of this reaction
1.9% of all CLOPIDOGREL reports
#11 most reported adverse reaction
CEREBROVASCULAR ACCIDENT is the #11 most commonly reported adverse reaction for CLOPIDOGREL, manufactured by Sanofi-Aventis U.S. LLC. There are 6,403 FDA adverse event reports linking CLOPIDOGREL to CEREBROVASCULAR ACCIDENT. This represents approximately 1.9% of all 332,980 adverse event reports for this drug.
Patients taking CLOPIDOGREL who experience cerebrovascular accident should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CEREBROVASCULAR ACCIDENT is a less commonly reported adverse event for CLOPIDOGREL, but still significant enough to appear in the safety profile.
In addition to cerebrovascular accident, the following adverse reactions have been reported for CLOPIDOGREL:
The following drugs have also been linked to cerebrovascular accident in FDA adverse event reports:
CEREBROVASCULAR ACCIDENT has been reported as an adverse event in 6,403 FDA reports for CLOPIDOGREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CEREBROVASCULAR ACCIDENT accounts for approximately 1.9% of all adverse event reports for CLOPIDOGREL, making it a notable side effect.
If you experience cerebrovascular accident while taking CLOPIDOGREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.